IMNM News and Press, Immunome Inc. From 12/26/23

2023-12-26 08:47:34 ET More on Atreca, Immunome, etc. Immunome: The Morphimmune Merger And The Pipeline Immunome a new outperform at Wedbush on cancer platforms Seeking Alpha’s Quant Rating on Atreca Historical earnings data for Atreca Financia...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets a...

CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that...

2023-12-19 13:43:38 ET More on Immunome Immunome: The Morphimmune Merger And The Pipeline Immunome files to sell 21.7M shares for holders For further details see: Immunome a new outperform at Wedbush on cancer platforms

2023-12-14 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-16 16:35:12 ET More on Immunome Immunome: The Morphimmune Merger And The Pipeline Financial information for Immunome For further details see: Immunome files to sell 21.7M shares for holders

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:0...

2023-11-09 13:12:06 ET More on Immunome Immunome: The Morphimmune Merger And The Pipeline Financial information for Immunome For further details see: Immunome GAAP EPS of -$0.36, revenue of $3.57M

- Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Med...

- Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors - Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, to...